You just read:

Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

News provided by

Mitsubishi Tanabe Pharma America, Inc.

May 02, 2019, 09:00 ET